Clinical Trials Logo

Clinical Trial Summary

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06111963
Study type Observational
Source National Cancer Institute, Egypt
Contact Walaa Y Elsabeeny, MD
Phone +201007798466
Email walaa.elsabeeny@nci.cu.edu.eg
Status Recruiting
Phase
Start date November 1, 2023
Completion date August 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03779347 - Schistosomiasis Diagnosis Using a CAA Antigen Test Phase 3
Terminated NCT01746940 - Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia Phase 3
Not yet recruiting NCT04800042 - Study of the Prevalence of Iron Deficiency in Patients With Scheduled Major Surgery (CARENFER PBM) N/A
Completed NCT05076188 - PARamedical Abnormalties Detection of Traumatic Bone Lesion of the extremitIeS
Completed NCT03832608 - Sarcopenia Cut-points and Functionality in Older Adults
Recruiting NCT06233539 - A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation
Completed NCT03250884 - Evaluation of the Performance of a Rapid Pregnancy Diagnostic Test.
Not yet recruiting NCT03495570 - Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections